Rafarma Pharmaceuticals, Inc.
RAFA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $7,197 | $22,934 | $38,508 | $73,264 |
| - Cash | $77 | $66 | $18,048 | $13,596 |
| + Debt | $0 | $0 | $909 | $1,701 |
| Enterprise Value | $7,120 | $22,868 | $21,369 | $61,369 |
| Revenue | $9,078 | $10,135 | $64,314 | $77,411 |
| % Growth | -10.4% | -84.2% | -16.9% | – |
| Gross Profit | $674 | $600 | $22,814 | $27,271 |
| % Margin | 7.4% | 5.9% | 35.5% | 35.2% |
| EBITDA | $342 | $527 | $6,454 | $14,725 |
| % Margin | 3.8% | 5.2% | 10% | 19% |
| Net Income | $266 | $273 | $4,961 | $11,573 |
| % Margin | 2.9% | 2.7% | 7.7% | 15% |
| EPS Diluted | 0.003 | 0.003 | 0.057 | 0.13 |
| % Growth | -3.2% | -94.5% | -56.5% | – |
| Operating Cash Flow | $44 | -$50,671 | $18,769 | $2,877 |
| Capital Expenditures | -$44 | $50,671 | -$12,081 | $0 |
| Free Cash Flow | $0 | $0 | $6,688 | $2,877 |